Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.
about
Increased Risk of Group B Streptococcus Invasive Infection in HIV-Exposed but Uninfected Infants: A Review of the Evidence and Possible MechanismsThe Immune System of HIV-Exposed Uninfected InfantsThe potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experiencePneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children.HIV-Exposed Uninfected Infants in Zimbabwe: Insights into Health Outcomes in the Pre-Antiretroviral Therapy Era.Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south africa: a matched case-control study.Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infantsLongitudinal study on Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus nasopharyngeal colonization in HIV-infected and -uninfected infants vaccinated with pneumococcal conjugate vaccine.The PneuCarriage Project: A Multi-Centre Comparative Study to Identify the Best Serotyping Methods for Examining Pneumococcal Carriage in Vaccine Evaluation StudiesVaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status.PCVs in individuals at increased risk of pneumococcal disease: a literature review.Increased risk for and mortality from invasive pneumococcal disease in HIV-exposed but uninfected infants aged <1 year in South Africa, 2009-2013.Immune responses to oral poliovirus vaccine in HIV-exposed uninfected Zimbabwean infants.The Effect of Human Immunodeficiency Virus and Cytomegalovirus Infection on Infant Responses to Vaccines: A Review.Outpacing the pneumococcus: Antibody dynamics in the first few days following pneumococcal capsular antigen stimulation
P2860
Q28067423-80051E17-26F6-4CF6-8B14-39E8ACFD6B1FQ28069872-FCA04775-DDFC-45BF-8E29-393AA7B0C405Q28088507-FCB74A01-0A8F-4963-9344-3241675EA1CFQ30235055-07375D82-B5CE-47E6-8464-2D7B4B0D5ECEQ30383065-F2F2140A-37E0-4781-8378-9CE5E72D582FQ34087769-03CD6F26-61A3-43CF-A149-38978F4BD59EQ34981631-C2EBFED5-5BC9-4574-A3E3-0253EEA52F44Q35621571-8F60DDC9-1E9A-40DA-BA94-6CEDFE8EB795Q35843459-6E0AC4D3-03EC-4D1D-8A2B-3358E25DCB0CQ37606399-5B9B2E27-F519-4B1B-9CC6-429C8D1BFCF9Q38530267-1725D171-2138-47DA-BCBA-D3CE6231F74BQ41489687-66B35E45-D5DB-40FF-951A-50F33AF4F5DFQ47131363-A61156F6-9D18-4FE5-81CC-53C9E775756BQ52649837-08BC61E8-C24F-498C-A8B7-D1411DEF7C62Q58476625-3E59E7F4-774A-4FFF-9302-30DC6F528F0F
P2860
Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Immunogenicity following the f ...... ected and -uninfected infants.
@en
type
label
Immunogenicity following the f ...... ected and -uninfected infants.
@en
prefLabel
Immunogenicity following the f ...... ected and -uninfected infants.
@en
P2093
P2860
P1433
P1476
Immunogenicity following the f ...... ected and -uninfected infants.
@en
P2093
Avye Violari
CIPRA-4 team
Els Dobbels
Mark F Cotton
Nadia van Niekerk
Patrick Jean-Philippe
Peter V Adrian
Poonam Sewraj
Ravindre Panchia
P2860
P304
P356
10.1016/J.VACCINE.2012.11.076
P407
P577
2012-12-08T00:00:00Z